A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

AbbVie

Status and phase: Enrolling; Phase 1

Conditions: Healthy Volunteer

Treatments: Drug: ABBV-932

Study type: Interventional

Funder types: Industry

Identifiers

NCT06849791

M24-889

Details and patient eligibility

About

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Enrollment: 42 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion criteria

• History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
• History of any clinically significant sensitivity or allergy to any medication or food.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

42 participants in 8 patient groups

ABBV-932: Arm A

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm B

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm C

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm D

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm E

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm F

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm G

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal.

Treatment:

Drug: ABBV-932

Drug: ABBV-932

ABBV-932: Arm H

Experimental group

Description:

Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions.

Treatment:

Drug: ABBV-932

Drug: ABBV-932